Blog Posts

Paving the Way for a New Class of Off-The-Shelf Cellular Cancer Vaccine – Cancer Research Institute

Icahn School of Medicine at Mount Sinai/X

Jul 24, 2025, 15:20

Paving the Way for a New Class of Off-The-Shelf Cellular Cancer Vaccine – Cancer Research Institute

Cancer Research Institute (CRI) shared a post on LinkedIn:

”Researchers from Icahn School of Medicine at Mount Sinai, including CRI Scientific Advisory Council Associate Director Dr. Nina Bhardwaj, have developed a novel method to generate billions of rare immune cells known as conventional type I dendritic cells (cDC1s), potentially paving the way for a new class of off-the-shelf cellular cancer vaccines.

“This is a major step toward the creation of universal cell-based cancer vaccines,” describes Dr. Bhardwaj. “Conventional type I dendritic cells are essential for mobilizing the immune system to fight cancer, but they’re almost impossible to obtain at scale. We’ve now overcome that barrier.”

Explore.”

More posts featuring Cancer Research Institute on OncoDaily.

cancer Cancer Research Institute Icahn School of Medicine at Mount Sinai Nina Bhardwaj off-the-shelf cellular cancer vaccines OncoDaily Oncology type I dendritic cells

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech